# Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

> **NCT00849667** · PHASE3 · TERMINATED · sponsor: **Morphotek** · enrollment: 1100 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Farletuzumab
- **DRUG:** Carboplatin
- **DRUG:** Taxane
- **DRUG:** Farletuzumab-matched placebo

## Key facts

- **NCT ID:** NCT00849667
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-16
- **Primary completion:** 2012-12-31
- **Final completion:** 2013-04-12
- **Target enrollment:** 1100 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2022-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849667, "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00849667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*